What is MedHub?
Founded in 2018 and headquartered in Tel Aviv, Israel, MedHub operates at the intersection of deep-tech and cardiology. The company specializes in developing sophisticated AI-driven tools designed to replace costly and invasive cardiac procedures. By focusing on high-precision image analysis, MedHub aims to reduce patient risk while simultaneously lowering the economic burden on healthcare systems. Its market position is defined by a commitment to clinical efficacy and the integration of machine learning into standard diagnostic workflows, effectively bridging the gap between complex medical imaging and actionable clinical insights.
How much funding has MedHub raised?
MedHub has raised a total of $1M across 1 funding round:
Unspecified
$1M
Unspecified (2022): $1M with participation from Ron Zuckerman and Prof. Rafael Beyar
Key Investors in MedHub
Ron Zuckerman
A prominent private investor and entrepreneur known for supporting high-growth technology ventures and medical innovation.
Prof. Rafael Beyar
A distinguished figure in the medical field, providing strategic guidance and capital to companies focused on advancing cardiac care and surgical technology.
What's next for MedHub?
With this major enterprise-level funding, MedHub is poised to accelerate its research and development pipeline and expand its clinical validation studies. The strategic allocation of this capital will likely focus on scaling its AI infrastructure and navigating the regulatory pathways necessary for broader international market entry. As the company transitions from its foundational phase into a period of rapid commercialization, the focus will remain on refining its algorithmic accuracy and establishing key partnerships with major hospital networks. This growth trajectory suggests a long-term objective of setting a new standard for non-invasive cardiac care, potentially reshaping the competitive landscape for medical device manufacturers globally.
See full MedHub company page
